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 INCOMPLETE PROTECTION AGAINST HEPATITIS B 
AMONG REMOTE ABORIGINAL ADOLESCENTS DESPITE 
FULL VACCINATION IN INFANCY
 Elizabeth Dent, Christine E  Selvey, Andrew  Bell, Joshua  Davis, Malcolm I  McDonald 
 Abstract 
 The objective of this study was to determine long-
term immunity to hepatitis B virus (HBV) in a cohort 
of adolescents who received plasma-derived HBV 
vaccine in 1989 and 1990 in a remote Australian 
Aboriginal community. This was done using a sero-
logical survey; primary outcome measures were 
cut-off titres of HBsAb, and the presence of HBcAb 
and/or HBsAg. Of 37 adolescents in the cohort, 
4 (11%) had evidence of active infection, one with 
abnormal liver enzymes, 7 (19%) had evidence of 
past infection, 15 (41%) were HBsAb positive in 
low titre and 11 (30%) were classed as immune. 
It was concluded that there was relatively poor 
long-term serological immunity to HBV vaccination 
in this group; a finding which is in keeping with 
similar studies in Indigenous and remote popula-
tions elsewhere. This finding raises the concern 
that a significant proportion of Aboriginal adoles-
cents in other remote communities (vaccinated in 
1989 and 1990) were not adequately protected 
by the vaccine. If so, there will be an unexpected 
burden of chronic HBV infection in these settings 
and a substantial group who are non-immune, 
despite having received complete HBV vaccination 
courses as infants. The authors recommend follow-
up serosurveys in remote Aboriginal communities 
to identify people with low HBsAb titres, especially 
those without an adequate anamnestic response 
to another dose of HBV vaccine. In addition, 
community-based active surveillance programs 
will be required to detect people with chronic 
HBV infection and provide access to monitoring 
and appropriate treatment.  Commun Dis Intell 
2010;34(4):435–439. 
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 Introduction
 The hepatitis B virus (HBV) vaccine was widely 
accepted and distributed soon after it became availa-
ble in the early 1980s. 1  Immunisation prevents HBV 
chronic liver disease and has dramatically reduced the 
incidence of hepatocellular carcinoma in vaccinated 
populations. 1  HBV vaccination was introduced into 
the Northern Territory Childhood Immunisation 
Schedule at birth, 1 month and 6 months of age 
for Aboriginal neonates in April 1988. Several years 
later, it became universal across Australia.
 Recent studies have suggested that immune 
responses to the early HBV vaccines may have been 
suboptimal in some Aboriginal communities. 2–5  In 
addition to factors related to the vaccination process, 
investigators have suggested that genetic, develop-
mental, and environmental factors may contribute 
to a poor response. 2–4 
 Studies in Mongolia and Indonesia have shown that 
improper storage and interrupted vaccine transport 
to remote settings can lead to freezing; this structur-
ally destabilises the vaccine and reduces efficacy. 6,7  A 
study in the Northern Territory, Australia, in 1994 
documented freezing temperatures in 47.5% of vac-
cines, either in transfer or during storage. 8  In rural 
China it was thought that similar transport factors 
could play a part, however it was found that genetic 
factors played a larger role, with a specific HLA 
haplotype predicting poor vaccine responses among 
the Han Chinese. 9 
 Two randomised controlled trials have reported long 
term follow-up of high risk populations wherein a 
small percentage of vaccinated persons with initial 
seroprotection later developed HBcAb, indicating 
that some individuals either did not remain, or were 
never protected by the vaccine. 10,11  Importantly, none 
of the subjects who developed HBcAb developed 
clinical hepatitis and the vaccine appears to have 
provided protection against chronic HBV disease. 
Maternal to infant transmission, prior to the first dose 
of vaccine, would also have been a plausible cause for 
the presence of HBcAb in these individuals.
 In 2004, a well men’s check in one remote 
Indigenous community in the Northern Territory 
found a 14-year-old male with active HBV infec-
tion and abnormal liver function. A review of his 
medical record showed that he had received all 
3 recommended vaccine doses, at the correct times, 
as an infant. Health centre staff knew of a second 
child of the same age in the community who had 
become HBV positive following contact with an 
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infected individual at age three. Both young people 
had also been fully vaccinated against HBV at the 
correct times. The hepatitis serology of their moth-
ers at birth is unknown. These findings prompted 
the medical staff to conduct a serosurvey of children 
in the community who had been vaccinated in 1989 
and 1990.
 This Aboriginal population was among the first to 
receive routine infant HBV vaccination and this is 
the first report of long term follow-up in a remote 
setting. The aim was to determine immunity to HBV 
in adolescents vaccinated with plasma derived HBV 
vaccine in infancy over a 2-year period (January 
1989 to December 1990). The outcome measures 
were:
1.  the prevalence of HBV infection as indicated by 
a positive test for HBV surface antigen (HBsAg) ,
2.  the rate of past exposure to HBV or vaccine as 
indicated by the titre of HBV surface antibody 
(HBsAb), 
3.  the rate of past HBV infection, indicated by the 
titre of HBV core antibody (HBcAb). 
 Methods
 Ethics approval was granted by the human research 
ethics committee of the Menzies School of Health 
Research and the Northern Territory Department of 
Health and Families. The governing Health Board 
gave permission to access relevant laboratory results. 
A clinic nurse matched pathology results to vaccina-
tion history, de-identified the data and provided it to 
the principal investigator. Permission was given by 
the appropriate Aboriginal Health Board to publish 
the results. The community general practitioner (GP) 
used the computerised clinical records system to iden-
tify children born to families in the community and 
neighbouring communities in 1989 and 1990. HBV 
vaccination details were retrieved for each individual. 
An Aboriginal Health Worker identified vaccinated 
adolescents currently living in the community and 
located those who had left. Forty-eight teenagers were 
identified but 11 could not be located, leaving a cohort 
group of 37. The GP obtained informed consent, col-
lected blood for serology between May and July 2005 
(15–16 years post vaccination) and counselled each 
person about the reasons for the test and the potential 
meaning of results.
 All samples were tested for HBsAb, HBcAb, and 
HBsAg. The Table outlines the relevance of each 
serological test. An HBsAb titre <10 mIU/ml with 
a negative HBcAb was taken as indication of immu-
nity due to vaccination. Post-vaccine immunological 
memory is defined as the case where HBbsAb titre 
< 10 mIU/ml and HBV exposure promotes a sec-
ondary immune response. 12  Low HBsAb titre could 
represent a lack of initial immune response, waning 
immunity, or a latent immune response that would 
be re-activated with exposure to the virus or vaccine. 
Immunological memory can be measured by testing 
HBsAb titre after a booster dose. 13 
 Results of testing were explained to adolescents and 
their parents. Adolescents with evidence of current 
infection (positive HBsAg) were listed for regular 
follow-up. The GP arranged further liver function 
tests and counselled the adolescents, and their par-
ents regarding the significance of the results.
 Results
 The GP screened 35 children, and two were tested 
by the school nurse at boarding school. The 11 ado-
lescents who could not be located are being kept on 
a list for follow-up should they return to the com-
munity.
 Of the 37 in the cohort, 4 (11%) had evidence of 
HBV infection, one with abnormal aminotrans-
ferase levels, 7 (19%) with evidence of past infection, 
15 (41%) were considered not to have seroprotection 
(0 mIU/ml < HBsAb < 10 mIU/ml), and 11 (30%) 
were classed as having seroprotection according to 
the cut-off (Figure). Of the 11 adolescents with evi-
dence of current or past HBV infection, all but one 
had received the first dose of vaccine at birth. One 
child had received the first dose at 1 month of age.
 Table:  Guide to hepatitis serology 
Abbreviation Meaning of abbreviation Explanation of HBV serology 
HBsAg Hepatitis B surface antigen Presence indicates current infection
HBsAb Hepatitis B surface antibody Presence indicates immunity 
HBcAb Tot Hepatitis B core antibody (total) Presence indicates current or past infection
HBcAbIgM Hepatitis B core antibody (IgM) Presence indicates recent acute infection
HBeAg Hepatitis B e Antigen Presence indicates highly infective stage 
HBe Ab Hepatitis B e Antibody Presence indicates reduced infectivity status 
 
 Adapted from Western Diagnostic Pathology 
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 Discussion
 Eleven fully vaccinated children (close to 30%) in 
this cohort showed evidence of past infection with 
HBV, and 4 had ongoing infection as determined 
by positive HBsAg. This compares with the study 
of Wood et al (2008) 5  (Australian Aboriginal Birth 
Cohort Study) who followed up 401 Aboriginal ado-
lescents aged 16–20 years, vaccinated across 50 com-
munities between 1987–1992. Evidence of past HBV 
infection was found in 21%, and 1.5% had persistent 
infection. Half were considered to have inadequate 
immunity and were given booster doses. In this 
cohort, only a third had received on-time childhood 
HBV vaccination in infancy. 5 
 Plasma derived vaccines were used before the 
introduction of recombinant vaccines in 1991, 14  
and when used in infancy, were accompanied by a 
relativity inferior anamnestic response. 15  Moreover, 
evidence-based guidelines for storage and transport 
of vaccines were not developed by the World Health 
Organization until 1992/1993. 16  A 1994 study con-
ducted in the Northern Territory tagged 144 vials 
of HBV and 127 vials of poliomyelitis vaccine dis-
tributed to community settings. The cold chain was 
breached frequently with 23% of temperatures too 
high and 47.5% too low. The more stages there were 
in transportation, and the more remote the setting, 
the higher the risk of being exposed to freezing tem-
peratures. 8  As a result, inclusion of freeze monitors is 
now considered best practice. Awareness of freezing 
has increased since cold chain monitoring became 
policy in Australia in 2001. 14  In 1989 and 1990, it is 
quite likely that some batches were frozen during 
transport or storage.
 Another consideration would be persistent mater-
nal–infant transmission despite proper vaccination. 
Hepatitis B immunoglobulin is recommended, in 
addition to infant vaccination, for the prevention 
of maternal–infant transmission. The HBsAg sta-
tus of the mothers at the time of birth of the study 
adolescents is not known. However, HBV has high 
prevalence in Indigenous communities. In 1987, 
the prevalence of HBV infection among non-met-
ropolitan Aboriginal women at prenatal screening 
in Western Australia was 3.6%. 17  Estimates of the 
population prevalence of HBV infection among 
Aboriginal populations in Western Australia and the 
Northern Territory have varied from 3%–22%. 17–21  
A recent East Arnhem Land survey found a high 
prevalence of chronic infection, with a prevalence of 
HBsAg in 12% of adults.  22 
 Several studies have demonstrated that infant vacci-
nation does not always prevent vertical transmission. 
In China, a long-term follow-up of 95 adolescents 
who were vaccinated with plasma derived hepatitis 
vaccine but not immunoglobulin at birth, 1 and 
2 months, and whose mothers had HBV infection, 
found 9% had evidence of past infection (positive 
HBcAb), though none developed clinical hepa-
titis. 23  In a similarly designed Canadian study, of 
770 children who had been vaccinated at birth with 
immunoglobulin followed by the plasma derived 
vaccination at 0, 1 and 2 months, 5% had developed 
HBcAb 24  when followed up at 8 years. Another 
5-year follow-up study of vaccinated infants of car-
rier mothers using recombinant vaccine found that 
12% (19/162) subsequently developed HBcAb by 
age 5 years (6/19 before age one) and that maternal 
HBcAb disappeared from the blood of the infant 
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in 99% of children before age 2 years. 25  While the 
post-birth period is the highest risk period for sero-
conversion, the infection might not be established or 
detected until as late as age two. 25
 Low birth weight (LBW), with or without prema-
turity, is common among Indigenous infants, and 
failure to thrive occurs more commonly than in the 
general Australian population. In addition, many 
infants live in crowded conditions, exposed to mul-
tiple childhood infections and life stressors. Infant 
mortality is unacceptably high. 26  Rates of seropro-
tection are lower for preterm compared with full 
term infants. 27  Theoretically, lack of immunological 
maturity in LBW infants could compromise vac-
cine response; however, when infection and other 
co-morbid illnesses are excluded, there appears to be 
no difference. 27  It is possible that prematurity, recur-
rent infection and ongoing poor nutrition in infants 
contribute to a suboptimal immune response.
 Some studies have suggested that lower immune 
response among Aboriginal infants is genetically 
determined. 2–4  Additionally, HBV vaccine escape 
mutants can lead to vaccine failure. 12,28  For practi-
cal reasons, neither HLA typing nor the presence 
of escape mutants could be assessed in this study 
setting.
 The size of the cohort was small and 11 adolescents 
could not be located; this raises concerns of potential 
attrition bias. A sensitivity analysis suggests that if all 
the missing subjects had evidence of past infection, 
the proportion with hepatitis infection would be 
22/48 (46%). If all 11 were immune, the proportion 
would have been 11/48 (23%), more in keeping with 
the expected infection rates in a population with a 
high rate of maternal infection.
 The major limitation of this study is that the pres-
ence of immunological memory was not investigated 
for those adolescents with HBsAb <10 mIU/ml and 
HBsAg negative. Therefore, the immune status 
of this subgroup was unclear. A similar 15-year 
follow-up study of Micronesian infants illustrates 
the importance of checking for immunological 
memory. A group of 105 children were vaccinated 
with recombinant vaccine in infancy. HBcAb was 
determined at baseline, at 35 months, and again 
after 15 years. 13  The rate of HBcAb in this study was 
much lower at 15 years post vaccination than in our 
study, 7.6% compared with 30%, and none became 
HBsAg positive. HBV booster doses were given to 
96 subjects without HBcAb to investigate immune 
memory; 47.9% had an anamnestic response. 13  If 
this study had tested immune memory in this way 
and found similar results, then around half the ado-
lescents may have an anamnestic response.
 No studies have demonstrated active HBV disease 
in vaccinated subjects (without renal failure) with 
initially documented seroprotection. Even though 
protective seroimmunity levels and the anamnestic 
response may wane over time, 10,11  they do not neces-
sarily constitute vaccine failure. There is probably 
still protection from progressive liver disease and 
hepatocellular carcinoma. 10,11  Further investiga-
tion should examine the possible benefits of post-
vaccination serological testing for high risk infants 
such as those in remote Aboriginal communities, as 
additional doses may result in seroconversion in a 
proportion of those who initially fail to respond to 
vaccination.
 The results of this study are a cause for concern. There 
may be a significant proportion of Aboriginal adoles-
cents vaccinated in 1989 and 1990 who have chronic 
HBV infection, and another substantial subset who 
are non-immune, despite having received complete 
HBV vaccination courses as infants. The authors 
recommend further investigation across remote 
Indigenous Australian populations to determine 
the proportion, location, and vaccine batch used in 
those whom vaccine failure has occurred and identify 
those who are not immune as well as those who are 
chronically infected. A systematic community-based 
program could be carried out as part of regular Adult 
Health Checks and is recommended to detect those 
with chronic HBV infection and provide access to 
ongoing monitoring and treatment
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